EntryPoint Capital LLC Sells 1,701 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

EntryPoint Capital LLC trimmed its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 39.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,586 shares of the biotechnology company’s stock after selling 1,701 shares during the quarter. EntryPoint Capital LLC’s holdings in Blueprint Medicines were worth $226,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in BPMC. Quarry LP bought a new stake in shares of Blueprint Medicines in the 3rd quarter valued at about $32,000. R Squared Ltd bought a new stake in Blueprint Medicines in the fourth quarter valued at approximately $51,000. Asset Management One Co. Ltd. acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $88,000. Van ECK Associates Corp boosted its stake in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 363 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Blueprint Medicines during the 3rd quarter worth approximately $108,000.

Blueprint Medicines Stock Down 1.1 %

Shares of BPMC opened at $88.72 on Friday. The firm has a 50 day simple moving average of $98.13 and a two-hundred day simple moving average of $93.99. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90. The company has a market cap of $5.67 billion, a P/E ratio of -82.15 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BPMC has been the subject of a number of research analyst reports. Stephens reaffirmed an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Wolfe Research assumed coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They issued an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Scotiabank assumed coverage on Blueprint Medicines in a report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and set a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Blueprint Medicines has an average rating of “Moderate Buy” and an average target price of $124.95.

Insider Transactions at Blueprint Medicines

In related news, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the transaction, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total transaction of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares in the company, valued at $6,581,655.32. This represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,608 shares of company stock valued at $3,319,587. 4.21% of the stock is currently owned by insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.